IgA nephropathy featuring massive wire loop-like deposits in two patients with alcoholic cirrhosis

Daisuke Takada1, Keiichi Sumida1, Akinari Sekine1*, Ryo Hazue1, Masayuki Yamanouchi1, Tatsuya Suwabe1, Noriko Hayami1, Junichi Hoshino1, Naoki Sawa1, Kenmei Takaichi1,3, Takeshi Fujii2, Kenichi Ohashi2,4 and Yoshifumi Ubara1,3*

Abstract

Background: Various renal manifestations are known to develop in patients with liver disease, including chronic hepatitis and cirrhosis.

Case presentation: We evaluated renal disease in two 47-year-old Japanese men with liver cirrhosis and chronic alcoholism for 34 years and 27 years, respectively. Renal biopsy demonstrated massive wire loop-like deposits in the subendothelial space of the glomerular basement membrane and in the mesangium. However, immunofluorescence was only positive for IgA and C3, and electron microscopy did not reveal any organized structures in the electron-dense deposits. IgA nephropathy was diagnosed, although the features were different from primary IgA nephropathy. Both patients had portosystemic shunts associated with liver cirrhosis. Their renal deposits and proteinuria resolved completely after 1 year of steroid therapy.

Conclusion: Alcohol abuse may have contributed to development of secondary IgA nephropathy in these two patients, probably via their portosystemic shunts.

Keywords: Wire loop-like subendothelial deposit, Alcoholic cirrhosis, IgA nephropathy

Background

Various renal manifestations are known to develop in patients with liver disease, including chronic hepatitis and cirrhosis. Three types of nephropathy have been reported in patients with hepatitis C virus (HCV) infection, including IgG-dominant nephropathies (such as membranous glomerulonephritis: MGN), IgA-dominant nephropathies (such as IgA nephropathy), and IgM-dominant nephropathies (such as type 1 membranoproliferative glomerulonephritis (MPGN), which corresponds to cryoglobulinemic glomerulopathy). The most common form of HCV-related renal disease is cryoglobulinemic glomerulopathy, which is closely associated with hypocomplementemia, liver cirrhosis, and elevation of serum HCV RNA [1–3]. On the other hand, the best-known renal complication of hepatitis B virus (HBV) infection is MGN. Type 1 MPGN with IgG dominant staining has also been reported in patients with HBV surface antigen positivity [3]. Although an animal study has shown that IgA nephropathy can be induced by alcohol abuse [4], glomerulonephritis specific to alcoholic liver disease has not been clearly defined and is categorized with cirrhosis-related secondary IgA nephropathy. In patients with cirrhosis-related IgA nephropathy, renal histologic changes are generally reported to be mild, consisting of slight to moderate mesangial expansion with or without mesangial hypercellularity [5].

Here we report two patients with alcoholic cirrhosis who developed IgA nephropathy featuring massive subendothelial deposits, and we document the response of their renal histology and proteinuria to steroid therapy.
Case presentations

Case 1
A 47-year-old Japanese man was admitted to our hospital for evaluation of renal disease in March 2009. Liver dysfunction was initially detected in December 2007. He consulted a local clinic in February 2008 because of generalized edema and weight gain from 70 kg to 78 kg. Proteinuria (4+) was also detected. His anasarca was treated with furosemide (150 mg daily) and restriction of salt and fluid intake (to 6 g of salt and 1000 mL of water daily). He had a history of drinking 1500 mL of beer daily for 27 years from the age of 20. On admission, he was 173 cm tall and weighed 70.6 kg. His blood pressure was 138/70 mmHg and he had bilateral lower limb edema. Laboratory findings are shown in Table 1. Total protein was 5.5 g/dL, albumin was 2.2 g/dL, urea nitrogen was 17 mg/dL, and creatinine (Cre) was 0.9 mg/dL. In addition, 24-h urinary protein excretion was 3.9 g and the urine sediment contained numerous erythrocytes per high-power field.

Computed tomography and ultrasonography showed enlargement of the paraumbilical veins (suggesting a portosystemic shunt), as well as hepatosplenomegaly and ascites. Small esophageal varices with a negative red color sign were detected by endoscopy.

Alcoholic cirrhosis was diagnosed from the 27-year history of alcohol abuse and negative test results for HBV and HCV infection. Renal biopsy was performed to evaluate the cause of his renal disease.

Findings at the first renal biopsy

Case 1
Light microscopy (LM) of the biopsy specimen revealed global sclerosis in 1 out of 25 glomeruli. In the other glomeruli, there was slight to moderate expansion of the mesangial matrix and mesangial cell proliferation, as well as massive wire loop-like amorphous subendothelial deposits in the glomerular basement membrane (GBM) and endothelial cell swelling (Fig. 1a). Immunofluorescence (IF) was positive for IgA (IgA1 > IgA2) and C3, predominantly in the mesangium and GBM, while there was no immunostaining for IgG, IgM, C4, and C1q (Fig. 1b). Electron microscopy (EM) showed massive electron-dense subendothelial deposits without any organized internal structure in the GBM and similar deposits in the mesangium (Fig. 1c). IgA nephropathy was diagnosed, although the renal histology differed from that of primary IgA nephropathy.

Case 2
LM revealed global sclerosis in 8 out of 24 glomeruli. The remaining glomeruli showed similar features to those noted in case 1 (Fig. 2a), and IF findings were also similar to those seen in case 1 (Fig. 2b). Furthermore, EM showed similar massive deposits to those detected in case 1 (Fig. 2c). Accordingly, atypical IgA nephropathy was diagnosed in this patient, as in case 1.

Clinical course

Case 1
Treatment was started with intravenous methylprednisolone (0.5 g daily for three days), followed by oral prednisolone (PSL) at a dose of 30 mg on alternate days. PSL was tapered by 5 mg every two months, and was discontinued after 1 year. An angiotensin II receptor blocker (olmesartan at 40 mg/day) was administered to treat hypertension. Six months after starting PSL, proteinuria was reduced to less than 0.1 g daily. Although complete remission of proteinuria was maintained after discontinuation of PSL, renal dysfunction persisted. Accordingly, a second renal biopsy was performed for re-evaluation of this patient’s renal disease at 1 year after the first biopsy.

Case 2
Treatment was initiated with the same regimen as that used in case 1 and was discontinued after 1 year.
Olmesartan (40 mg/day) was also administered for hypertension. Three months after starting PSL, proteinuria was reduced to less than 0.1 g daily and complete remission of proteinuria was maintained after discontinuation of PSL. However, renal dysfunction also persisted in this patient, so renal biopsy was repeated for re-evaluation of his renal disease after 1 year.

Findings at the second renal biopsy

Case 1
LM of the biopsy specimen revealed global sclerosis in 3 out of 14 glomeruli, while the remaining glomeruli showed marked improvement compared with the initial findings (Fig. 1d). IF demonstrated weaker IgA and C3 staining compared with that at the time of the first biopsy (Fig. 1e), while EM revealed disappearance of the massive subendothelial and mesangial electron-dense deposits (Fig. 1f).

Case 2
LM of the biopsy specimen displayed global sclerosis in 5 out of 23 glomeruli, along with marked improvement of the changes in the remaining glomeruli (Fig. 2d). As in case 1, IF showed weaker staining for IgA and C3 compared to the first biopsy (Fig. 2e), while EM revealed elimination of the massive subendothelial and mesangial electron-dense deposits (Fig. 2f).

Discussion
Alcohol abuse is a very common clinical problem, with an estimated lifetime prevalence of 18% among adults in the United States, and a report in 2010 estimated that

---

### Table 1 Laboratory findings of case 1 before and after 1 year of steroid therapy

|                      | Before | After 1 year | Normal range |
|----------------------|--------|--------------|--------------|
| White blood count, /μl | 4600   | 6600         | 3400–9200    |
| Red blood cell, x10*4/μl | 4.2    | 2.61         | 400–566      |
| Hemoglobin, g/dl       | 13.4   | 9            | 13.0–17.0    |
| Hematocrit, %          | 41.36  | 28           | 38.2–50.8    |
| Platelet, x10*4/μl     | 17.6   | 13           | 14.1–32.7    |
| Total protein, g/dl    | 5.5    | 6.8          | 6.9–8.4      |
| Albumin, g/dl          | 2.2    | 2.7          | 3.9–5.2      |
| Total bilirubin, mg/dl | 1.5    | 2.6          | 0.3–1.1      |
| AST, IU/l              | 60     | 70           | 13–33        |
| ALT, IU/l              | 38     | 36           | 8–42         |
| LDH, IU/l              | 204    | 250          | 119–229      |
| CK, IU/l               | 62     | 42           | 62–287       |
| ALP, IU/l              | 232    | 304          | 117–350      |
| yGTP, IU/l             | 140    | 358          | 9–109        |
| LAP                    | 54     | 63           | 21–42        |
| CHE                    | 184    | 143          | 220–495      |
| T-Chol                 | 174    | 210          | 120–240      |
| TG                     | 76     | 151          | 30–150       |
| NH3                    | 91     | 62           | 6–51         |
| HbA1c                  | 4.7    | 4.6–6.2      |              |
| UN, mg/dl              | 17     | 17           | 8–12         |
| Creatinine, mg/dl      | 0.9    | 1.1          | 0.65–1.06    |
| eGFR                   | 72.1   | 57.9         | >100         |
| Urinary acid, mg/dl    | 6.5    | 7.7          | 2.5–7.0      |
| Na, mmol/l             | 140    | 139          | 139–146      |
| K, mmol/l              | 4.2    | 4            | 3.7–4.8      |
| Cl, mmol/l             | 104    | 102          | 101–108      |
| APPT, sec              | 41.7   | 31.1         | 27–40        |
| PT, %                  | 79.4   | 53.2         | >75          |
| INR                    | 1.15   | 1.3          |              |
| ICG15R(%)              | 58     | 32           | <10          |
| IgG, mg/dl             | 740    | 947          | 870–1700     |
| IgA, mg/dl             | 1110   | 845          | 110–410      |
| IgM, mg/dl             | 162    | 190          | 35–220       |
| IgF, mg/dl             |         |              | <173         |
| C3, mg/dl              | 66     | 78           | 86–160       |
| C4, mg/dl              | 13     | 15           | 17–45        |
| CH50, U/ml             | 31     | 35           | 30–50        |

### Table 1 Laboratory findings of case 1 before and after 1 year of steroid therapy (Continued)

|                      | Before | After 1 year | Normal range |
|----------------------|--------|--------------|--------------|
| HCV                  | negative | negative |              |
| HBV                  | negative | negative |              |
| CRP, mg/dl           | 0.1    | 0.1          | 0.0–0.3      |
| Urinalysis            |         |              |              |
| Sediment             |         |              |              |
| RBC /HPF             | many   | 1 to 4       | <1           |
| WBC /HPF             | 6–10   | –            | <1           |
| Cast                 | None   | None         | <1           |
| protein, g/day       | 3.94   | 0.04         | <0.1         |
| Glucose              | negative | negative |              |
| NAG, IU/day          | 14.3   | 8.9          | 0.8–5.0      |
| α1 MG, mg/day        | 8.1    | 2.1          | 0.6–8.8      |
| β2 MG, mg/day        | 46     | 30           | 14–329       |

---
alcohol-related cirrhosis was responsible for 493,300 deaths worldwide (1% of all deaths) [6]. In 1942, Horn et al. first identified glomerulonephritis in an autopsy case of liver cirrhosis without diabetes [7]. In 1983, Endo et al. evaluated renal disease in 50 cirrhosis patients at autopsy, detecting membranoproliferative glomerulonephritis (MPGN type 1) and mesangial proliferative glomerulonephritis with or without subendothelial deposits. Predominant deposition of IgA was a characteristic finding in these patients. The causes of cirrhosis included alcohol abuse, HBV infection, and non A-non B virus infection, but the relation between an alcoholic etiology and glomerular changes was not reported [8].

In 2009, Kaartinen et al. examined the relation between alcohol intake and IgA nephropathy in 158 patients (95 men), and concluded that moderate alcohol consumption might have a favorable impact on the progression of IgA nephropathy [9]. Koning et al. studied the association between alcohol consumption and chronic kidney disease (CKD) in 5476 persons aged 28 to 75 years, and found an inverse correlation between alcohol consumption and the risk of developing CKD [10].

After reviewing previous reports, Newel concluded that more than 50% of autopsy patients with cirrhosis have mesangial IgA deposits together with complement deposition and elevation of serum IgA. They suggested that spread of circulating immune complexes via porto-systemic shunts may be involved in the pathogenesis of renal lesions [11].

Tissandie et al. analyzed IgA-associated serum parameters in 32 patients with compensated or advanced alcoholic cirrhosis. They reported various similarities between primary IgA nephropathy and secondary IgA nephropathy in patients with alcoholic cirrhosis, since

| Table 2 Laboratory findings of case 2 before and after 1 year of steroid therapy (Continued) |
|----------------------------------|---------------------|---------------------|
| Before | After 1 year | Normal range |
| HCV | negative | negative |
| HBV | negative | negative |
| CRP, mg/dl | 0 | 0 | 0.0–0.3 |
| Urinalysis | Sediment |
| RBC, /HPF | many | 1 to 4 | <1 |
| WBC, /HPF | 1–4 | – | <1 |
| Cast | None | None | <1 |
| protein, g/gCre | 1.17 | 0.01 |
| Glucose | negative | negative | negative |
| NAG, IU/day | 14.3 | 8.9 | 0.8–5.0 |
| α1 MG, mg/day | 8.1 | 0.4 | 0.6–8.8 |
| β2 MG, mg/day | 14 | 19 | 14–329 |

| Table 2 Laboratory findings of case 2 before and after 1 year of steroid therapy |
|----------------------------------|---------------------|
| White blood count, /μl | 10,300 | 8700 | 3400–9200 |
| Red blood cell, x10^4/μl | 4.14 | 3.95 | 400–566 |
| Hematocrit, % | 12.4 | 11.1 | 13.0–17.0 |
| Platelet, x10^4/μl | 36.6 | 34.5 | 38.2–50.8 |
| Total protein, g/dl | 14.7 | 18.6 | 14.1–32.7 |
| Albumin, g/dl | 6 | 6.5 | 6.9–8.4 |
| Total bilirubin, mg/dl | 2.7 | 2.8 | 3.9–5.2 |
| AST, IU/l | 0.6 | 0.5 | 0.3–1.1 |
| ALT, IU/l | 65 | 32 | 13–33 |
| LDH, IU/l | 38 | 10 | 8–42 |
| CPK, IU/l | 231 | 234 | 119–229 |
| ALP, IU/l | 118 | 94 | 62–287 |
| yGTP, IU/l | 298 | 298 | 117–350 |
| LAP, IU/l | 172 | 63 | 9–109 |
| eGFR | 54 | 21–42 |
| Urinary acid, mg/dl | 204 | 220–495 |
| Na, mmol/l | 172 | 137 | 120–240 |
| TG | 111 | 167 | 30–150 |
| K, mmol/l | 31 | 38 | 6–51 |
| Cl, mmol/l | 4.9 | 4.6 | 4.6–6.2 |
| APTT, sec | UN, mg/dl | 23 | 21 | 8–12 |
| Creatinine, mg/dl | 1.66 | 1.55 | 0.65–1.06 |
| eGFR | 36.8 | 47.5 |
| Urinary acid, mg/dl | 9.3 | 6.7 | 2.5–7.0 |
| Na, mmol/l | 144 | 141 | 139–146 |
| K, mmol/l | 4.2 | 5 | 3.7–4.8 |
| Cl, mmol/l | 107 | 110 | 101–108 |
| APTT, sec | 25.9 | 30.9 | 27–40 |
| PT, % | 99.3 | 89.5 | >75 |
| INR, | 1 | 1 |
| ICG15R(%) | 27 |
| IgG, mg/dl | 958 | 1195 | 870–1700 |
| IgM, mg/dl | 519 | 324 | 110–410 |
| IgA, mg/dl | 149 | 1216 | 35–220 |
| IgE, mg/dl | 88.9 | 1216 | <173 |
| C3, mg/dl | 62 | 89 | 86–160 |
| C4, mg/dl | 17 | 37 | 17–45 |
| CH50, U/ml | 34 | 42 | 30–50 |
| ANA | negative | negative |
| anti ds-DNA | negative | negative |
| anti RNP | negative | negative |
| anti mito | negative | negative |
| Cryoglobulin | negative | negative |
features of primary nephropathy such as abnormal glycosylation of IgA1 and soluble CD89-IgA or IgA-IgG complexes were also present in cirrhosis patients. However, IgA1 displayed modified N-glycosylation in patients with alcoholic cirrhosis that was not found in primary IgA nephropathy [12].

IgA nephropathy is the renal disease most frequently associated with prominent mesangial deposition of IgA, and it mainly occurs in Asians and Caucasians. Primary IgA nephropathy is characterized by elevation of serum IgA, the absence of systemic features, and the following renal biopsy findings: LM shows mesangial hypercellularity and an increase of matrix, IF demonstrates IgA staining (often accompanied by C3) in the mesangium and lesser staining along the glomerular capillary walls, and EM typically reveals electron-dense deposits that are primarily limited to the mesangium. Henoch-Schönlein purpura (HSP), also called IgA vasculitis, is a systemic vasculitis associated with palpable purpura, arthritis, abdominal pain, and renal disease. While the renal lesions are similar to those of primary IgA nephropathy, the following points can be used for differentiation. First, LM can show a wide spectrum of glomerular changes in HSP, ranging from isolated mesangial proliferation to severe crescentic glomerulonephritis. In addition, IF may reveal glomerular deposition of IgG, IgM, fibrinogen, and C3 in HSP. EM typically shows electron-dense deposits in the mesangial region, which occasionally extend out into the peripheral capillary loops [13, 14].

There have been two reports showing a close relationship between the existence of a portosystemic shunt and mesangial IgA deposition. Dash et al. performed a prospective study in 200 patients with non-cirrhotic portal fibrosis (NCPF) and bleeding from esophageal varices due to portal hypertension who underwent spleno-renal shunt surgery, after which the portal
circulation directly entered the inferior vena cava via the renal vein. In 32% of these patients, nephrotic syndrome developed within five years after surgery. Renal biopsy revealed mesangiocapillary glomerulonephritis in 18.5% of them, while IF showed granular deposits of IgA and C3, and EM demonstrated electron-dense deposits in the mesangium [15]. In addition, Soma also reported three patients who developed type I membranoproliferative glomerulonephritis (MPGN) with IgA deposits from 7 to 13 years after portosystemic shunt surgery [16]. These reports indicate that IgA from the gastrointestinal tract may contribute to the development of IgA nephropathy if it reaches the systemic circulation via a portosystemic shunt.

**Conclusion**
We evaluated renal disease in two Japanese men with alcoholic cirrhosis. Renal biopsy revealed IgA nephropathy characterized by glomerular immunostaining for IgA. However, LM showed massive wire loop-like amorphous deposits in the mesangial and subendothelial regions along with endothelial cell swelling, and EM disclosed huge electron-dense deposits without an organized internal structure. Both patients had alcoholic liver cirrhosis with a portosystemic shunt, and their massive renal deposits were completely eliminated after 1 year of steroid therapy. Because renal histologic changes are generally reported to be mild in patients with cirrhosis-related IgA nephropathy [5], it seems that excessive alcohol intake may have been related to the severity of nephropathy in these two patients and might have contributed to development of secondary IgA nephropathy resembling the extensive renal involvement seen in HSP, probably due to the influence of portosystemic shunting.

**Abbreviations**
CG: Cryoglobulinemic glomerulopathy; HCV: Hepatitis C virus; IgAN: IgA nephropathy; MGN: Membranous glomerulonephritis; MPGN: Membranoproliferative glomerulonephritis

---

**Fig. 2** a: Case 2: LM of the first renal biopsy specimen demonstrates massive wire loop-like deposits of amorphous material similar to those seen in case 1. b: IF displays similar findings to case 1. c: EM reveals massive deposits similar to those seen in case 1. d: LM of the second renal biopsy specimen shows marked improvement of the glomerular changes. e: IF displays weaker staining for IgA and C3 compared to the first biopsy. f: Massive EDD are no longer shown by EM.
Acknowledgments
This study was funded by the Okinaka Memorial Institute for Medical Research. We gratefully acknowledge the members of the renal pathology working group, including Shigee Hara(Kobe University), Michio Nagata (Tukuba University). Yutaka Yarnaguchi, Nobuaki Yamanaka, and Hidekazu Shigematsu, for their evaluation of renal histology, as well as Motoko Yanagita for valuable discussion. I would like to thank Hiroki Mizuno, Junko Nitta, Koki Mise, Toshiharu Ueno for contributing discussing this case.

Availability of data and materials
All the data supporting our findings is contained within the manuscript.

Authors’ contributions
DK contributed to analyzing and interpretation of images of the manuscript. RS contributed to analyzing and interpretation of data and writing the manuscript. KS contributed to analyzing and interpretation of data and writing the manuscript. KO contributed to analyzing and interpretation of pathological findings. KT contributed to analyzing and interpretation of data and management the patient. RJH contributed to managing the patient and assessing data. NH contributed to managing the patient and assessing data. RH contributed to managing the patient and assessing data. AS contributed to managing the patient and assessing data. DK contributed to analyzing and interpretation of data and writing the manuscript. KS contributed to analyzing and interpretation of data and writing the manuscript. AS contributed to managing the patient and assessing data.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Informed consent was obtained from the patients for publication of this case report and any accompanying images.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Nephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, Kanagawa 213-8587, Japan. 2Department of Pathology, Toranomon Hospital, Tokyo, Japan. 3The Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan. 4Department of Pathology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.

Received: 28 August 2016 Accepted: 20 November 2017
Published online: 13 December 2017

References
1. Sunmida K, Ubara Y, Hoshino J, Suwabe T, Nakanishi S, Hiramatsu R, Hasegawa E, Hayami N, Yamanouchi M, Sawa N, Takemoto F, Takaichi K, Oohashi K. Hepatitis C virus-related kidney disease: various histological patterns. Clin Nephrol. 2010;74(6):446–56.
2. Hiramatsu R, Hoshino J, Suwabe T, Sunmida K, Hasegawa E, Yamanouchi M, Hayami N, Sawa N, Takaichi K, Ohashi K, Fuji T, Ubara Y. Membranoproliferative glomerulonephritis and circulating cryoglobulins. Clin Exp Nephrol. 2014;18(1):88–94.
3. Zhou XJ, Silva FG. Membranoproliferative glomerulonephritis. In: Jennette JC, Olson JL, Silva FG, D’Agati VD, editors. Heptinstall’s pathology of the kidney. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 328–31.
4. Smith SM, Yu GS, Tsukamoto H. IgA nephropathy in alcohol abuse. An animal model. Lab Invest. 1996;32(1):79–84.
5. Haas M, IgA nephropathy and IgA vasculitis. In: Jennette JC, Olson JL, Silva FG, D’Agati VD, editors. Heptinstall’s pathology of the kidney. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 496–9.
6. Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013;59(1):160–8.
7. Horn RC, Smetana H. Intercapillary Glomerulosclerosis. Am J Pathol. 1942;18(1):93–9.
8. Endo Y, Matsuhashi H, Nozawa Y, Nishikage S, Matsu S, Hara M. Glomerulonephritis associated with liver cirrhosis. Acta Pathol Jpn. 1983;33(2):333–46.
9. Kaartinen K, Niemela O, Sjørøen J, Porstl I, Harmoinen A, Pasternack A, Huhatala H, Mustonen J. Alcohol consumption and kidney function in IgA glomerulonephritis. Nephron Clin Pract. 2009;112(2):c86–93.
10. Koning SH, Gansvooort RT, Mukamal KJ, Rimm EB, Baiker SJ, Joosten MM. PREVEND study group alcohol consumption is inversely associated with the risk of developing chronic kidney disease. Kidney Int. 2015;87(5):1009–16.
11. Newell GC. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis. 1997;9(3):183–90.
12. Tissandie E, Morelle W, Berthelot I, Vrtovsnik F, Daugas E, Walker F, Lebrec D, Trawalé JM, Francoz C, Durand F, Moura IC, Paradis V, Moreau R, Monteiro RC. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int. 2011;80(12):1352–63.
13. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402.
14. Galla JH. IgA nephropathy. Kidney Int. 1995;47(2):377–87.
15. Dash SC, Bhuyan UN, Dinda AK, Saxena S, Agawan SK, Tiwari SC, Nundy S. Increased incidence of glomerulonephritis following spleno-renal shunt surgery in non-cirrhotic portal fibrosis. Kidney Int. 1997;52(2):482–5.
16. Soma J, Saito T, Sato H, Ootaka T, Abe K. Membranoproliferative glomerulonephritis induced by portosystemic shunt surgery for non-cirrhotic portal hypertension. Clin Nephrol. 1997;48(5):274–81.